Table 1 3 [3] factorial design optimization outcomes for ganciclovir ophthalmic in situ gel optimization
From: In-situ gel bases ocular delivery system of Ganciclovir, in-vivo and in-vitro investigation
Formulation code | Concentration of Ganciclovir (%w/v) | Concentration of poloxamer (%w/v) | Concentration of HPMC E-50 LV (%w/v) | Concentration of Methyl paraben (%w/v) | Concentration of Triethanolamine (%v/v) |
|---|---|---|---|---|---|
B1 | 0.15 | 05 | 1.00 | 0.1 | 0.1 |
B2 | 0.15 | 10 | 0.75 | 0.1 | 0.1 |
B3 | 0.15 | 05 | 0.75 | 0.1 | 0.1 |
B4 | 0.15 | 15 | 0.50 | 0.1 | 0.1 |
B5 | 0.15 | 15 | 1.00 | 0.1 | 0.1 |
B6 | 0.15 | 15 | 0.75 | 0.1 | 0.1 |
B7 | 0.15 | 10 | 1.00 | 0.1 | 0.1 |
B8 | 0.15 | 10 | 0.50 | 0.1 | 0.1 |
B9 | 0.15 | 05 | 0.50 | 0.1 | 0.1 |